No Data
No Data
TD Cowen Initiates Inventiva(IVA.US) With Buy Rating, Announces Target Price $10
Inventiva Initiated With a Buy at TD Cowen
Express News | Inventiva Shares Are Trading Lower. The Company Announced the Initiation of the Clinical Development Program of Lanifibranor in Japan With the First Japanese Participant Dosed in a Phase 1 Clinical Trial Evaluating the Safety, Tolerability,...
Inventiva And Hepalys Launch Phase 1 Trial Of Lanifibranor In Japan For MASH, Targeting Japanese Market With 32 Participants; Results May Lead To Phase 3; Milestone In Partnership For Expansion In Japan And South Korea
Buy Rating for Inventiva: Strategic Focus on Lanifibranor and Strong Financial Outlook
LifeSci Capital Maintains Inventiva(IVA.US) With Buy Rating, Maintains Target Price $14
Unlock the Full List